Cost‐effectiveness Analysis of Sintilimab Plus IBI305 Versus Sorafenib for Unresectable Hepatic Cell Carcinoma in China
CANCER MEDICINE（2023）
Key words
cost-effectiveness,hepatocellular carcinoma,Markov model,sintilimab,sorafenib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined